Smith & Nephew is targeting a serious margin ramp-up and tax rate reductions within the next few years. Maintaining its aggressive acquisition strategy is an obvious means to work toward both those goals.
3D Systems missed Wall Street earnings expectations because of product delays. The newly disclosed acquisition of Simbionix by 3D Systems for $120 million in cash went largely unnoticed as a consequence; the deal is designed to add 3D virtual reality surgical simulation capabilities to the 3D printer.
While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.
Meda has staunchly refused every takeover bid that's come its way. But that doesn't mean the Swedish drugmaker isn't interested in M&A. It just prefers to be the buyer. Meda says it's agreed to buy the family-owned Italian drugmaker Rottapharm for about 21.2 billion kronor ($3.1 billion), with an eye on its consumer health offerings.
AstraZeneca has agreed to pay $875 million up front--and up to $2.2 billion total, with milestones--for Almirall's respiratory portfolio. The deal brings a couple of marketed drugs, and a list of pipeline meds that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.
No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.
Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.
AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.
Nobel Biocare has confirmed it is in early discussions with potential buyers, after a Bloomberg article reported a rumored sale. The report said the company has hired Goldman Sachs to broker a transaction.
Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon.